We need to keep chipping away at the reservoir until there's nothing there.
For decades, antiretroviral therapy has kept HIV suppressed but never vanquished — the virus persists in silent cellular hiding places, waiting for the moment treatment stops. Researchers at the University of North Carolina have taken a careful step toward confronting this hidden reservoir, combining a drug that coaxes dormant HIV into the open with engineered immune cells designed to destroy what emerges. The results, published in early 2024, were modest rather than triumphant, yet they illuminate both the shape of the problem and the direction of the search — a reminder that in medicine, as in most human endeavors, the path to transformation is rarely straight.
- HIV's ability to lie dormant inside cells means that even people living well on antiretroviral therapy carry a hidden biological time bomb that reactivates the moment treatment stops.
- The UNC trial's two-pronged strategy — using vorinostat to unlock sleeping virus and engineered immune cells to kill what surfaces — showed only one of six participants responding in the first phase, raising questions about whether the approach could work at scale.
- When researchers increased the dose of engineered immune cells fivefold, all three participants in the second phase showed measurable reservoir reduction, offering a fragile but real signal worth pursuing.
- Vorinostat's effectiveness window of roughly one day severely limits the therapy's reach, and scientists now recognize that longer-acting latency-reversal agents are essential before this strategy can become clinically meaningful.
- The trial's modest statistical results fall short of a breakthrough, but the years-long commitment of altruistic participants — who gave blood, time, and procedures with no personal medical benefit — ensures the research foundation is solid enough to build upon.
Modern antiretroviral drugs have turned HIV into a manageable condition, allowing people to suppress the virus to undetectable levels for decades. But the virus never truly disappears — it hides in dormant cells, and the moment treatment stops, it returns. Eliminating this hidden reservoir is the difference between lifelong medication and an actual cure.
A team at the University of North Carolina, led by Cynthia Gay and David Margolis, set out to test a two-pronged strategy: use a drug called vorinostat to wake the sleeping virus, then deploy engineered immune cells to destroy what surfaces. Vorinostat works by loosening the protein scaffolding that keeps HIV's genetic material locked away and invisible to the immune system. The problem is that its effect lasts only about a day, leaving a narrow window for any immune response to act.
Six long-term research participants — people living with HIV who had been donating blood and time for years with no personal medical benefit — received multiple doses of vorinostat, followed by infusions of their own enhanced immune cells. In the first phase, only one of the six showed any reservoir decline. When the team increased the immune cell dose fivefold in a second phase, all three participants tested showed slight improvement. Yet the gains remained too small to claim statistical significance.
Margolis was candid about the disappointment, while framing the results as necessary groundwork. The findings make clear that better latency-reversal drugs — ones that work longer and more powerfully — are essential before this approach can reach its potential. The participants' years of baseline data gave the results whatever meaning they carry, and their continued commitment, Margolis noted, makes future trials possible. The search for a cure goes on, its path now more clearly mapped if not yet shorter.
Modern antiretroviral drugs have transformed HIV from a death sentence into a manageable chronic condition. People taking these medications can suppress the virus to undetectable levels and live decades without developing AIDS. But there is a catch: the virus does not disappear. It hides inside cells in a dormant state, waiting. The moment someone stops taking their pills, HIV wakes up, begins replicating again, and the disease returns. Finding a way to flush out this hidden reservoir and destroy it has become one of the central challenges in HIV research—the difference between lifelong medication and an actual cure.
A team at the University of North Carolina School of Medicine, led by infectious disease specialists Cynthia Gay and David Margolis, decided to test whether they could coax the virus out of hiding and then attack it. Their approach combined two strategies: first, a drug called vorinostat to unlock the cells where HIV sleeps, and second, engineered immune cells designed to recognize and kill the newly exposed virus. The results, published in the Journal of Infectious Diseases, showed that the combination could work—but only barely.
To understand how vorinostat functions, picture DNA as an impossibly long string wound tightly around protein scaffolds called histones, like thread wrapped around spools. This packaging keeps the genetic code organized and protected, but it also keeps dormant HIV locked away and invisible to the immune system. Vorinostat works by blocking an enzyme that acts like a lock on this packaging. When the lock releases, the DNA unwinds slightly, the chromatin fibers open, and latent HIV begins to express itself—to wake up. On sensitive molecular tests, researchers can detect this tiny flicker of viral activity. But the effect is fleeting. A single dose of vorinostat lasts only about a day, which means the window of vulnerability closes quickly.
The researchers recruited six participants living with HIV who had been working with the team for years, donating blood and time for research that offered them no immediate medical benefit. They gave these participants multiple doses of vorinostat, then extracted their white blood cells and grew them in the laboratory, enhancing the cells' ability to recognize and attack HIV-infected targets. This immunotherapy approach had worked against other viruses like Epstein-Barr and cytomegalovirus. The engineered cells were then returned to the participants' bodies, where researchers hoped they would multiply and launch an assault on the newly exposed infected cells.
The results were underwhelming. In the first phase of the trial, only one of the six participants showed any decline in their latent HIV reservoir. Margolis and his team wondered whether this single success was meaningful or simply chance. They tested a modified approach: three participants received their usual vorinostat dose, but this time they were infused with five times as many engineered immune cells. All three showed a slight reduction in their reservoir. Yet even this modest improvement fell short of statistical significance—the gains were too small to declare a genuine breakthrough.
Margolis acknowledged the disappointment with candor. The team had hoped for more substantial results, but the work needed to be done. The findings pointed toward clear next steps: researchers need better drugs to pull HIV out of latency, and they need those drugs to work longer than a single day. They also need more potent immune responses, or perhaps entirely different strategies altogether. The path to an HIV cure remains open, but it is longer and more complex than this trial revealed.
What made the modest results somewhat more compelling was the long-term partnership with study participants. Many had been tracking their viral reservoirs with Margolis's team for years before this trial began, providing a detailed baseline against which to measure change. These participants came in multiple times annually, gave blood samples, and submitted to procedures that offered them nothing in return—a purely altruistic contribution to research. Without their sustained commitment, Margolis noted, none of this progress would have been possible. The work continues, with researchers already designing newer approaches and hoping to launch additional trials soon.
Notable Quotes
The reductions were not nearly large enough, and statistically speaking were what we call a 'trend' but not highly statistically significant.— David Margolis, director of the HIV Cure Center
People living with HIV come in a couple of times a year, and we measure residual traces of virus in their blood cells, which doesn't have any immediate benefit to them. It's a very altruistic action.— David Margolis
The Hearth Conversation Another angle on the story
Why does HIV hide in the first place? Why can't the drugs we have just kill it everywhere?
Because HIV is clever. When antiretroviral drugs suppress viral replication, the virus that's already integrated into cell DNA just goes dormant—it stops making copies of itself, so the immune system can't see it. It's like the virus is holding its breath. The drugs work perfectly at stopping new infection, but they can't wake up something that's already asleep.
So vorinostat is essentially an alarm clock.
Exactly. It unlocks the chromatin packaging that keeps the dormant virus hidden. Once the virus starts expressing itself again, the immune system can theoretically recognize it and attack. But vorinostat only works for about a day per dose, which is the real problem.
Why is that a problem if you can just give more doses?
Because the window is so short. You'd need to keep dosing the drug while simultaneously having enough active immune cells ready to attack. The timing has to be perfect, and the immune response has to be strong enough. In this trial, even when they increased the engineered immune cells fivefold, the reduction in the reservoir was still barely measurable.
So they failed.
Not exactly. They proved the concept works—they did reduce the reservoir in some participants. But the reductions were so small that statistically they could be noise. It's like saying you found a leak in a dam and plugged it, but the water level barely dropped. You've learned something real, but you haven't solved the problem.
What do the participants get out of this?
Nothing immediate. They donate blood, undergo procedures, take experimental drugs—all for data that might help someone else years from now. That's the sacrifice these six people made, and Margolis was clear that without that kind of commitment, this research doesn't happen at all.